Cintredekin Besudotox

Summary

Cintredekin Besudotox (CHEMBL2108583) is a phase-3 clinical-stage protein; indicated across 9 conditions including glioblastoma and oligoastrocytoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 9 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108583
Name	Cintredekin Besudotox
Type	Protein
Max phase	3

Also known as: Cintredekin besudotox, Cintredekina besudotox, Cintredekine besudotox, CINTREDEKIN BESUDOTOX

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glioblastoma	3	MONDO:0018177	EFO:0000519
oligoastrocytoma	1	MONDO:0016702	EFO:0000630
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	1	MONDO:0016696	EFO:0002501
brain neoplasm	1	MONDO:0021211	EFO:0003833
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158
glioma	1	MONDO:0021042	MONDO:0100342
astrocytoma (excluding glioblastoma)	1	MONDO:0019781	EFO:0000272
paraganglioma	1	MONDO:0000448	EFO:1000453

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE1/PHASE2	5
PHASE1	5
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00076986	PHASE3	COMPLETED	The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
NCT00006268	PHASE1/PHASE2	COMPLETED	Immunotoxin Therapy in Treating Patients With Malignant Glioma
NCT00024570	PHASE1/PHASE2	COMPLETED	Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
NCT00041587	PHASE1/PHASE2	COMPLETED	Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
NCT00053040	PHASE1/PHASE2	WITHDRAWN	Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
NCT00378235	PHASE1/PHASE2	WITHDRAWN	Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
NCT00024557	PHASE1	COMPLETED	Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
NCT00036972	PHASE1	COMPLETED	Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
NCT00064779	PHASE1	COMPLETED	Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
NCT00089427	PHASE1	COMPLETED	IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
NCT00880061	PHASE1	TERMINATED	An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).